Compare BCYC & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCYC | NUS |
|---|---|---|
| Founded | 2009 | 1984 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.7M | 343.1M |
| IPO Year | 2019 | 1996 |
| Metric | BCYC | NUS |
|---|---|---|
| Price | $4.54 | $5.60 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $13.90 | N/A |
| AVG Volume (30 Days) | 296.1K | ★ 617.5K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.36% |
| EPS Growth | N/A | ★ 207.80 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $3,176,718,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.14 |
| P/E Ratio | ★ N/A | $143.63 |
| Revenue Growth | N/A | ★ 48.98 |
| 52 Week Low | $4.24 | $5.62 |
| 52 Week High | $9.36 | $14.62 |
| Indicator | BCYC | NUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 26.07 |
| Support Level | $4.52 | N/A |
| Resistance Level | $5.22 | $7.50 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 52.38 | 5.17 |
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.